Medtronic plc (MDTN.MX)

1 455,00 0,00 (0,00 %) À partir de 09:07AM CST. Marché ouvert.

Medtronic plc

20 On Hatch
Lower Hatch Street
Dublin 2
Ireland
353 1 438 1700
https://www.medtronic.com

Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 95 000

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Geoffrey Straub Martha	Chairman of the Board & CEO	32,21M	S.O.	1970
Ms. Karen L. Parkhill	Executive VP & CFO	17,82M	S.O.	1965
Mr. Sean M. Salmon	Executive VP & President of Cardiovascular Portfolio	16,18M	7,52M	1965
Mr. Robert J. W. ten Hoedt	Executive VP & President of Global Regions	22,25M	1,72M	1960
Mr. Mark Ploof	Senior Vice President of Global Operations and Business Services	S.O.	S.O.	S.O.
Ms. Jennifer M. Kirk	Senior VP, Global Controller & Chief Accounting Officer	S.O.	S.O.	1975
Dr. Kenneth E. Washington Ph.D.	Senior VP and Chief Technology & Innovation Officer	S.O.	S.O.	1960
Dr. Laura Mauri M.D., M.Sc.	Senior VP and Chief Scientific & Medical Officer	S.O.	S.O.	S.O.
Mr. Ryan Weispfenning	VP & Head of Investor Relations	S.O.	S.O.	S.O.
Mr. Ivan K. Fong	Executive VP, General Counsel & Secretary	17,7M	S.O.	1961

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en MXN.

Description

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Medtronic plc en date du 1 juin 2024 est 6. Les scores principaux sont Audit : 9; Société : 5; Droits des actionnaires : 6; Compensation : 3.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.